A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury
A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury
复制标题
DOI：
10.1097/ccm.0b013e318218669d
复制
发表时间：
2011-07-01
影响因子：
8.8
通讯作者：
Neff, Margaret J.
中科院分区：
文献类型：
--
作者：
Stapleton, Renee D.;Martin, Thomas R.;Neff, Margaret J.
Objectives: Administration of eicosapentaenoic acid and docosahexanoic acid, omega-3 fatty acids in fish oil, has been associated with improved patient outcomes in acute lung injury when studied in a commercial enteral formula. However, fish oil has not been tested independently in acute lung injury. We therefore sought to determine whether enteral fish oil alone would reduce pulmonary and systemic inflammation in patients with acute lung injury.Design: Phase II randomized controlled trial.Setting: Five North American medical centers.Patients: Mechanically ventilated patients with acute lung injury >= 18 yrs of age.Interventions: Subjects were randomized to receive enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosahexanoic acid daily) or saline placebo for up to 14 days.Measurements and Main Results: Bronchoalveolar lavage fluid and blood were collected at baseline (day 0), day 4 +/- 1, and day 8 +/- 1. The primary end point was bronchoalveolar lavage fluid interleukin-8 levels. Forty-one participants received fish oil and 49 received placebo. Enteral fish oil administration was associated with increased serum eicosapentaenoic acid concentration (p
